Ignite Creation Date:
2024-07-17 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475846
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-06-13
Brief Title:
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
Sponsor:
Fujian Shengdi Pharmaceutical Co Ltd
Organization:
Fujian Shengdi Pharmaceutical Co Ltd
Study Overview
Official Title:
A Evaluate HRS5580 for Injection for Prevention of Postoperative Nausea and Vomiting Efficacy and Safety of Ⅱ Period Randomized Multicenter Dose of Exploration Positive Control Placebo-controlled Double-blind Double Simulation Trials
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to evaluate the efficacy and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None